At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Leronlimabdrug
Likely dose
Leronlimab 525 mgAI-extracted
Key inclusion· 9
- ✓Histologically or cytologically confirmed locally advanced or metastatic solid tumor with disease progression on standard therapy, no subsequent approved treatment available after progression, unable to receive standard therapy, or for which standard therapy does not exist
- ✓CCR5 positive by IHC with >10% membranous staining or high predominance of CCR5+ tumor-infiltrating leukocytes, confirmed at reference laboratory
- ✓Measurable disease per RECIST v1.1
- ✓Age ≥18 years
Key exclusion· 6
- ✕Participation in another investigational study or receipt of investigational therapy within 28 days prior to enrollment
- ✕History of allergic reactions to compounds of similar chemical or biologic composition to leronlimab
- ✕Prior exposure to CCR5 antagonists
- ✕Known active CNS metastases or carcinomatous meningitis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Leronlimab for Solid Tumor, Adult. Completed, enrolled 16 participants across 1 site.
Detailed Summary
A single arm phase II study with 30 patients of leronlimab (PRO 140) in patients with CCR5+ locally advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Adult
CountriesUnited States
CollaboratorsAmarex Clinical Research
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartMay 2020
First PostedAug 2020
Primary CompletionNov 2021
Study CompletionJan 2025
TodayJul 2026
First PostedAug 7, 2020
Enrollment StartMay 1, 2020
Primary CompletionNov 7, 2021
Study CompletionJan 27, 2025
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.9 years ago
Interventions
Leronlimabdrug
Drug: Leronlimab 525mg